title: Reforming antiretroviral price negotiations and public procurement: the Mexican experience.
abstract: Since antiretroviral (ARV) medicines represent one of the most costly components of therapy for HIV in middle-income countries, ensuring their efficient procurement is highly relevant. In 2008, Mexico created a national commission for the negotiation of ARV prices to achieve price reductions for their public HIV treatment programmes. The objective of this study is to assess the immediate impact of the creation of the Mexican Commission for Price Negotiation on ARV prices and expenditures. A longitudinal retrospective analysis of procurement prices, volumes and type of the most commonly prescribed ARVs procured by the two largest providers of HIV/AIDS care in Mexico between 2004 and 2009 was carried out. These analyses were combined with 26 semi-structured key informant interviews to identify changes in the procurement process. Prices for ARVs dropped by an average of 38% after the first round of negotiations, indicating that the Commission was successful in price negotiations. However, when compared with other upper-middle-income countries, Mexico continues to pay an average of six times more for ARVs. The Commission's negotiations were successful in achieving lower ARV prices. However, price reduction in upper-middle-income countries suggests that the price decrease in Mexico cannot be entirely attributed to the Commission's first round of negotiations. In addition, key informants identified inefficiencies in the forecasting and procurement processes possibly affecting the efficiency of the negotiation process. A comprehensive approach to improving efficiency in the purchasing and delivery of ARVs is necessary, including a better clarification in the roles and responsibilities of the Commission, improving supply data collection and integration in forecasting and procurement, and the creation of a support system to monitor and provide feedback on patient ARV use.
authors.affiliation: School of Public Health, University of California, Berkeley, CA, USA
authors.forename: Adebiyi
authors.initials: A
authors.lastname: Adesina
authors.forename: Veronika J
authors.initials: VJ
authors.lastname: Wirtz
authors.forename: Sandra
authors.initials: S
authors.lastname: Dratler
mesh_terms: D019380:Anti-HIV Agents / Q000191:economics* / Q000627:therapeutic use; D003363:Cost Control / Q000379:methods; D016527:Drug Costs / Q000706:statistics & numerical data; D005380:Financing, Government / Q000191:economics / Q000458:organization & administration*; D006077:Government Agencies / Q000458:organization & administration; D015658:HIV Infections / Q000188:drug therapy; D006801:Humans; D008800:Mexico; D017008:Negotiating
chemical_list: D019380:Anti-HIV Agents